Navigation Links
Chimerix Initiates Phase 1 Study of CMX157
Date:5/13/2010

RESEARCH TRIANGLE PARK, N.C., May 13 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the commencement of a first-in-human study of CMX157, a novel lipid conjugate of the nucleotide tenofovir with in vitro activity against both tenofovir-sensitive and tenofovir-resistant human immunodeficiency virus (HIV). CMX157 has the potential to increase efficacy and decrease toxicity as compared to tenofovir, and may enable the creation of new 'one pill, once-a-day', fixed-dose combination regimens for the treatment of HIV infection.

The Phase 1 dose-escalating clinical study is designed to evaluate the safety, tolerability and pharmacokinetics (PK) of CMX157. Healthy volunteers will receive a single-dose of CMX157 (25 mg, 50 mg or 100 mg), a standard dose of tenofovir (as Viread®) or placebo. In addition to monitoring safety and standard PK parameters in plasma, levels of the active antiviral (tenofovir diphosphate) will be determined in peripheral blood mononuclear cells (PBMCs). These data will provide insight into the potential efficacy of CMX157, as the levels of tenofovir diphosphate in PBMCs associated with the antiviral efficacy of Viread have been documented.

"We are pleased to advance CMX157 into human clinical studies. While advances in HIV treatment have resulted in longer life spans, HIV is known to develop resistance to currently approved agents and significant drug side effects remain an issue for many patients," said Wendy Painter, M.D., MPH, Chimerix's Chief Medical Officer. "We are extremely encouraged by preclinical data that show CMX157 to be highly potent and less toxic than current HIV drugs and believe it has the potential to become an important new antiviral therapy."


'/>"/>
SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Chimerix Names George Painter, Ph.D., Chairman of the Board and Chief Scientific Officer; Appoints Kenneth I. Moch President and Chief Executive Officer
2. Chimerix Names Wendy Painter, M.D., M.P.H., as Chief Medical Officer
3. Chimerix, Inc. Appoints Kenneth I. Moch Chief Operating Officer
4. Chimerix Joins International Network of Organizations to Cure Malaria
5. Chimerix Completes Phase I Study and Initiates a Phase II Multi-dose Clinical Trial for CMX001
6. Merial to Screen Chimerix Chemical Library for Animal Health Drug Leads
7. Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer
8. Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent AF
9. EnVivo Initiates Phase IIb Alzheimers Disease Trial For EVP-6124
10. Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.
11. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1/2 Combination Study of MM-121 and Tarceva in Patients with Non-Small Cell Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... (PRWEB) , ... August 28, 2015 , ... Since the initial launch of FireflySci Inc. ... quirky humor and excellent customer service. Images such as the Fonz in a lab ... add some flavor to the humdrum spectroscopy field. , FireflySci is proud to ...
(Date:8/27/2015)... , Aug. 27, 2015 The National ... patient,s eyes—and life—were saved by doctors at Vanderbilt University ... with NNFF, NovaBay Pharmaceuticals and Dr. John Crew ... at Seton Medical Center in Daly ... used a breakthrough approach, pioneered by Dr. Crew, that ...
(Date:8/27/2015)... ... ... Inc. Magazine released its annual list of the 5,000 fastest-growing privately held ... the three years through 2014. Being named to the Inc. 5000 list designates a ... , “We are thrilled to make the Inc. 5000 list for 2015,” stated ...
(Date:8/26/2015)... 2015 /PRNewswire/ - iCo Therapeutics ("iCo" or "the Company") ... for the quarter ended June 30, 2015. Amounts, ... and presented under International Financial Reporting Standards ("IFRS"). ... to our Oral Amp B program, rapidly advancing ... Andrew Rae , President & CEO of ...
Breaking Biology Technology:Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 2Patient's Life and Eyes Saved from Gruesome Flesh-Eating Infection Consuming Her Face 3iLab Solutions Named to 2015 Inc. 5000 List 2iLab Solutions Named to 2015 Inc. 5000 List 3iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3
... The Plasma Protein Therapeutics Association (PPTA) recommends that ... necessary steps to improve drug reimbursement under the Hospital ... week,s Advisory Panel on Ambulatory Payment Classification (APC) Groups ... to remove hospitals that purchase drugs under the 340B ...
... 2011 CBI is pleased to announce the full ... Studies Congress, being held September 20-22, 2011 in Philadelphia, ... speaker lineup from Celgene, Covidien, FDA, Forest, Ironwood Pharmaceuticals, ... Attendees have the opportunity to customize their ...
... YORK, Aug. 18, 2011 Reportlinker.com announces ... available in its catalogue: ... http://www.reportlinker.com/p0588171/Global-Genetic-Testing-Market-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Genomics In ... testing represents a highly attractive segment. Genetic ...
Cached Biology Technology:PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies 2PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies 3PPTA Urges CMS for Appropriate Hospital Outpatient Reimbursement for Plasma Protein Therapies 4FDA, NIH to Speak at CBI's 14th Annual Registries and Post-Approval Studies Congress 2Global Genetic Testing Market Analysis 2Global Genetic Testing Market Analysis 3
(Date:8/3/2015)... 2015 Synaptics, Inc. (Nasdaq: SYNA ), ... that members of the executive management team will present ... Technology Leadership Forum on Tuesday, August 11, 2015 at ... at the Sonnenalp Resort in Vail, CO. ... forward-looking information. An audio webcast of the event will ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julho de 2015 ... Genômica (ICG-10, www.icg-10.org ) será realizada pela BGI de ... China . A conferência está ... inauguração em 2006, a ICG se tornou uma das ... e um dos encontros científicos mais dinâmicos, entusiastas e ...
(Date:7/31/2015)... Die 10. internationale Konferenz zu Genomik (ICG-10, ... vom 22. bis 25. Oktober 2015 in ... Die Konferenz feiert in diesem Jahr ihr ... ICG weltweit zu einem der einflussreichsten jährlichen Treffen ... dynamischsten, enthusiastischsten und angenehmsten wissenschaftlichen Zusammentreffen. ...
Breaking Biology News(10 mins):A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 2Die 10. internationale Konferenz zu Genomik (ICG-10) beginnt im Oktober 3
... Women now dominate the field of veterinary medicine the ... repeat itself in the fields of medicine and law. ... factors that appear to be driving the change: the 1972 ... to graduate schools who may be deterred by a growing ...
... of the School of Policy Studies at Queen,s University, ... at an international think tank on "The Arctic and ... The Canada-UK Colloquium is organized annually by Queen,s ... to generate discussion and research about issues of immediate ...
... 2010 - An investigation conducted in the context of the ... Animals and Ecosystems, demonstrates for the first time that internal ... In the course of the Summer and Fall 2004, ... mothers who had given birth at the University Women,s Hospital ...
Cached Biology News:Vet med's big shift to more women, fewer men driven by falling barriers, more female grads 2Vet med's big shift to more women, fewer men driven by falling barriers, more female grads 3Vet med's big shift to more women, fewer men driven by falling barriers, more female grads 4Exposure of humans to cosmetic UV filters is widespread 2Exposure of humans to cosmetic UV filters is widespread 3
... B-Bridge's siSolutions RNAi Services offer ... for your siRNA studies. B-Bridges advanced ... and technical expertise ensure that you ... experiments. siSolutions siRNA Design Service utilizes ...
... Complete Solution Polymorphic DNA ... We provide a complete solution for SNP ... assay design, oligonucleotide primers, PCR amplification, DNA ... For SNP discovery, Polymorphic uses ...
... The mini ReadySub-Cell GT cell and PowerPac basic ... electrophoresis of nucleic acids in agarose gels. The ... with cables and electrodes, and leveling bubble. The ... provides output of 10-300 V, 4-400 mA, and ...
... This CE-based system provides clear ... quantitation (viral load, gene expression), mutation ... The easy-to-use system with microplate connectivity ... development, and quality control. The ...
Biology Products: